| Gene symbol | CLDN18 | Synonyms | SFTA5, SFTPJ | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q22.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | claudin 18 | ||||
| GTO ID | GTC3180 |
| Trial ID | NCT05539430 |
| Disease | Esophageal Cancer | Gastroesophageal Cancer | Pancreatic Cancer | Stomach Cancer |
| Altered gene | CLDN18 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | LB1908 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | Legend Biotech USA Inc |
| Other ID(s) | LB1908-1001 |
| Cohort 1 | |||||||||
|
|||||||||